Fonar Corporation (FONR) is a publicly traded Healthcare sector company. As of May 21, 2026, FONR trades at $18.89 with a market cap of $118.81M and a P/E ratio of 0.00. FONR moved -0.08% today. Year to date, FONR is +2.05%; over the trailing twelve months it is +33.73%. Its 52-week range spans $12.00 to $18.95. Rallies surfaces FONR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in FONR news today?
FONAR to Sell CEO-Linked Class B Shares at $19 and Class C at $6.34: FONAR Corporation will sell Class B shares to affiliates of CEO Timothy Damadian and company executives for $19.00 per share and Class C shares for $6.34 per share. An investor rights law firm is investigating potential fiduciary breaches and may seek higher compensation or additional disclosures for shareholders.
Bonanni Luciano B bought 3.40K (~$48.14K) on Sep 30, 2022.
Damadian Timothy Raymond bought 2.20K (~$31.13K) on Sep 30, 2022.
Bonanni Luciano B bought 1.30K (~$17.97K) on Sep 29, 2022.
FONR Analyst Consensus
FONR analyst coverage data. Average price target: $0.00.
Common questions about FONR
What changed in FONR news today?
FONAR to Sell CEO-Linked Class B Shares at $19 and Class C at $6.34: FONAR Corporation will sell Class B shares to affiliates of CEO Timothy Damadian and company executives for $19.00 per share and Class C shares for $6.34 per share. An investor rights law firm is investigating potential fiduciary breaches and may seek higher compensation or additional disclosures for shareholders.
Does Rallies summarize FONR news?
Yes. Rallies summarizes FONR news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is FONR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for FONR. It does not provide personalized investment advice.
